Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies

ABSTRACT: A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies

PROVIDER: PRJNA1006429 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies

Project description:Immunotherapy has emerged as a frontline approach in cancer management, aiming to enhance the adaptive immune response against tumors. However, its limited efficacy across a narrow range of tumor types necessitates the exploration of novel strategies that target innate immunity. Therapeutic modulation of pattern recognition receptors (PRRs) and innate immune cells holds promise in tumor eradication. β-glucan, a pathogen-associated molecular pattern (PAMP), acts as an immunostimulator, bridging the innate and adaptive immune responses. It exhibits low toxicity and high compatibility with various antitumor strategies. Plenty of clinical trials are ongoing to evaluate β-glucan-based cancer immunotherapy and shows promising clinical benefits across multiple cancer types. A soluble β-1,3/1,6-glucan with high purity from Durvillaea Antarctica (BG136) was reported previously by our group to exhibit pan antitumor effects alone as an immune stimulator. In current study, we proved the antitumor activity of BG136 in combination with anti-PD-1 antibodies in MC38 syngeneic tumor model in vivo. Integrated transcriptomic and metabolomic analyses suggest that BG136 enhances the antitumor immunity of anti-PD-1 antibodies by reprogramming tumor microenvironment to more proinflammatory status. There are more innate and adaptive immune cell infiltration and activation, enhanced lipid metabolism, decreased ascorbate and aldarate metabolism. These findings provide mechanistic insights supporting the potent antitumor efficacy of BG136 in combination with immune checkpoint inhibitor antibodies.

2024-12-31 | GSE241125 | GEO

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies II

2024-12-31 | GSE242577 | GEO

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies II

Project description:A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies II

| PRJNA1013965 | ENA

Immune response to intra-ocular injection of particulate β-(1,3)(1,6) glucan

Project description:Immune response to intra-ocular injection of particulate β-(1,3)(1,6) glucan

| PRJNA1023918 | ENA

Durvillaea antarctica

Project description:Durvillaea antarctica overview

| PRJNA980328 | ENA

Durvillaea antarctica

Project description:Durvillaea antarctica Genome sequencing and assembly

| PRJNA979950 | ENA

Immune response to intra-ocular injection of particulate β-(1,3)(1,6) glucan

Project description:Description of cellular and molecular landscape of vitreal immune cells following optic nerve crush injury plus intra-ocular injection of particulate β-glucan after 3days, in WT and Itgam-/- mice

2024-07-03 | GSE244627 | GEO

Durvillaea antarctica

Project description:Durvillaea antarctica (southern bull-kelp) GBS data

| PRJNA412568 | ENA

Expression data from toll-like receptor 9 (TLR9) knockout macrophages stimulated with β-1,3 glucan beads

Project description:Dectin1 controls the recruitment of TLR9 to β-1,3 glucan beads containing phagosomes. We sought to determine whether Dectin-1 also plays a role in controlling TLR9 dependent gene expression.

2015-09-28 | GSE73474 | GEO

Commensal yeast derived b-1,6-glucan induces regulatory T cells

Project description:Commensal yeast derived b-1,6-glucan induces regulatory T cells

| PRJNA523809 | ENA